The expiration of the semaglutide patent sparked a global conversation about the balance between innovation protection and market access. In Brazil, that same tension is playing out in a less visible but equally high-stakes arena: agribusiness. At the center of the conflict are agricultural biotech patents, royalties allegedly charged beyond their legal term, and a bill that could reshape IP rules across multiple industries.
The Intacta RR2 PRO Case: Patents, Soybeans, and R$5 Billion at Stake
The Intacta RR2 PRO technology, developed by Monsanto and later acquired by Bayer, is present in approximately 80% of Brazil’s soybean fields. It offers resistance to pests and herbicides, reducing operational costs for farmers, who pay royalties in return.
The issue: several of the patents underpinning those royalties have already expired.
Judicial investigation revealed that:
- Patent PI9816295-0 expired in March 2018
- Patent PI0016460-7 expired in December 2020
- Patent PI0610654-4, still active, expires in May 2026
Despite these expirations, Aprosoja-MT (the Mato Grosso Soybean Producers Association) argues that full royalties were still charged. With average soybean profitability at roughly R$85.50 per hectare and royalties of approximately R$280 per hectare, two-thirds of which allegedly relate to expired patents, farmers claim they have been paying for technology that should legally be in the public domain.
State courts in Mato Grosso ruled in favor of producers in both the first and second instances, ordering reimbursement of improperly charged fees, plus interest and a monetary correction. Estimated amounts exceed R$5 billion in that state alone, with similar cases pending in Bahia, Goiás, Piauí, Tocantins, and Rio Grande do Sul.
Bill No. 5810/2025: Reform or New Risk?
Running parallel to this dispute is Bill No. 5810/2025, which proposes compensating for delays at the Brazilian Patent and Trademark Office (BPTO) by extending patent protection by up to 5 years.
The bill has support from innovation-driven industries but faces strong opposition. A coalition of agribusiness and pharmaceutical associations warns of serious risks:
- Creation of artificial monopolies with unpredictable timelines
- Delayed market entry of post-patent products
- Higher costs for essential medicines and agricultural inputs
- Prevention of mature technologies from entering the public domain
There is also a significant constitutional hurdle: Brazil’s Supreme Court (STF), in its ruling on ADI 5529, declared unconstitutional the extension of patent terms based on administrative delays at the BPTO — casting serious doubt on the bill’s legal viability.
Key Takeaways for International Companies
For foreign companies operating or investing in Brazil — particularly in pharma, agtech, or biotech — this case carries important strategic implications:
- Patent due diligence is non-negotiable before any licensing deal or technology acquisition in Brazil
- A valid BPTO registration does not rule out litigation — courts may challenge charges retroactively
- Pending legislative changes could affect patent term strategies and IP asset planning
- Brazilian courts and trade associations increasingly scrutinize transparency in licensing
The Intacta case is a striking example of how poor management of a patent portfolio’s lifecycle can generate billion-dollar liabilities and structural conflicts with business partners. For IP rights holders in Brazil, actively monitoring patents and maintaining transparency in licensing relationships is not just best practice — it is a strategic imperative.
Tavares IP advises patent holders, licensees, and international companies in Brazil at all stages of the IP lifecycle. Contact us to learn how to protect and manage your assets with legal certainty.
